These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 30531684)
1. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients. He J; Liu Y; Zhang L; Zhang H Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray. Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656 [TBL] [Abstract][Full Text] [Related]
3. Increased DHRS12 expression independently predicts poor survival in patients with high-grade serous ovarian cancer. Zhang Y; Wu J; Jing H; Huang G; Dong J; Cui Z Future Oncol; 2018 Oct; 14(25):2579-2588. PubMed ID: 29783891 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma. Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524 [No Abstract] [Full Text] [Related]
6. LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer. Zeng Z; Ji N; Yi J; Lv J; Yuan J; Lin Z; Liu L; Feng X Cancer Biomark; 2020; 28(1):65-72. PubMed ID: 32176632 [TBL] [Abstract][Full Text] [Related]
7. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501 [TBL] [Abstract][Full Text] [Related]
8. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer]. Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477 [No Abstract] [Full Text] [Related]
9. Prognostic Significance of Increased Expression of Annexin A10 (ANXA10) in Serous Epithelial Ovarian Cancer. Wang J; Zhao S; Wang F; Wang J; Zhang Y Med Sci Monit; 2019 Jul; 25():5666-5673. PubMed ID: 31363077 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma. Zhu J; Ke G; Bi R; Wu X J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma. Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884 [TBL] [Abstract][Full Text] [Related]
12. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma. Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848 [TBL] [Abstract][Full Text] [Related]
13. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer. Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978 [TBL] [Abstract][Full Text] [Related]
16. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer. Hillman RT; Chisholm GB; Lu KH; Futreal PA J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920 [TBL] [Abstract][Full Text] [Related]
17. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
18. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition. Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796 [TBL] [Abstract][Full Text] [Related]
19. High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer. Qin L; Li T; Liu Y PLoS One; 2017; 12(11):e0187385. PubMed ID: 29091960 [TBL] [Abstract][Full Text] [Related]
20. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma. Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]